Physicians and leaders from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will attend the 2017 American Psychiatric Association (APA) annual meeting in San Diego, CA from May 20 – 24.

Five leading orthopedists and rehabilitation specialists, Drs. Aditya Derasari, Libi Galmer, Kevin Jiang, Raymond Pahk and Kevin Pak, have joined NewYork-Presbyterian Medical Group/Queens, working under Dr. Jeffrey Rosen, chairman, Department of Orthopedics and Rehabilitation at NewYork-Presbyterian/Queens. They are seeing patients at the new Orthopedics and Sports Medicine Center in Jackson Heights, which celebrated its grand opening on June 2 this year.

St. John’s University and NewYork-Presbyterian Queens announced a partnership today that makes NewYork-Presbyterian Queens the official hospital of Red Storm Athletics.

On Sunday, March 12 at 2:00 a.m., Daylight Saving Time, we advance our clocks forward an hour to better utilize sunlight. While many lament “the loss” of an hour’s sleep, setting our clocks forward one hour can indeed disturb our sleep patterns and leave us groggy for several days.

In an effort to reduce the number of people who die needlessly from sudden cardiac arrest each year, NewYork-Presbyterian and the Ronald O. Perelman Heart Institute have launched the #HandsOnlyCPR campaign, an ambitious community awareness, education and activation effort with a simple, but powerful message: Everyone Can Save a Life.

Dr. Ralf Holzer, a pediatric cardiologist and expert in minimally invasive techniques to treat children and adults with congenital heart disease, has been named chief of the Division of Pediatric Cardiology at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and director of Pediatric Cardiac Catheterization at The Komansky Children’s Hospital, effective June 1.

NewYork-Presbyterian Brooklyn Methodist Hospital recently held its 2017 Nurse Recognition Awards Ceremony. More than 130 staff members were honored at the ceremony, including 13 who received special recognition.

An immunotherapy drug used in combination with a traditional cancer drug could be an effective approach to treating a rare cancer known as sarcoma, according to a new study. Co-authored by Dr. Gary Schwartz, chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center, the study found that a combination of nivolumab, a common cancer drug, and ipilimumab, an immunotherapy drug, is safe and effective for sarcoma patients who have tried all other options.